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http:WHAT PAPER ADDS
Delay in the treatment of critical limb ischaemia with tissue loss has rarely been investigated, even if the
common conception is that these patients require treatment without delay. In this retrospective study, the
whole treatment process from referral to revascularisation in all its diversity and complexity is presented. The
impact of delay and how rapid revascularisation is essential for diabetic patients is demonstrated.Objectives: The number of elderly people is increasing; inevitably, the result will be more patients with critical
limb ischaemia (CLI) in the future. Tissue loss in CLI is related to a high risk of major amputation. The aim of this
study was to analyze the treatment process from referral to revascularisation, to discover possible delays and
reasons behind them, and to distinguish patients beneﬁtting the most from early revascularisation.
Methods: A retrospective analysis was performed of 394 consecutive patients with a combined 447 affected
limbs, referred to the outpatient clinic during 2010e2011 for tissue loss of suspected ischaemic origin.
Results: For 246 limbs revascularisation was scheduled. After changes in the initial treatment strategy,
endovascular treatment (ET) was performed on 221 and open surgery (OS) on 45 limbs. Notably there was
crossover after ET in 17.0% of the procedures, and re-revascularisations were required in 40.1% after ET and
31.1% after OS. The median time from referral to revascularisation was 43 days (range 1e657 days) with no
signiﬁcant difference between ET and OS. For 29 (11.8%) patients the ischaemic limb required an emergency
operation scheduled at the ﬁrst visit to the outpatient clinic. For 25 (10.2%) patients the situation worsened
while waiting for elective revascularisation and an emergency procedure was performed. Diabetic patients
formed the majority of the study population, with 159 diabetic feet undergoing revascularisation. In multivariate
analysis, diabetes was associated with poor limb salvage. When revascularisation was achieved within 2 weeks,
no difference was seen in limb salvage. However, when the delay from ﬁrst visit to revascularisation exceeded 2
weeks, limb salvage was signiﬁcantly poorer in diabetic patients.
Conclusions: Diabetic ulcers always require vascular evaluation, and when ischaemia is suspected the diagnostics
should be organised rapidly to ensure revascularisation without delay, according to this study within 2 weeks
from the ﬁrst evaluation.
 2016 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Ulcer formation in an ischaemic limb is a sign of critical
limb ischaemia (CLI), the most severe form of peripheral
artery disease (PAD). The prevalence of CLI and ischaemic
ulcers is rising with the aging population and the growing
number of diabetic patients. PAD is estimated to affect 9e
24%1e3 of diabetic patients during their lifetime, and
analogously 8e25%1,4 of diabetic patients are estimated to
develop a foot ulcer.responding author. Työmiehenkatu 4 a 13, 00180 Helsinki, Finland.
il address: katariina.noronen@hus.ﬁ (K. Noronen).
-5884/ 2016 European Society for Vascular Surgery. Published by
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//dx.doi.org/10.1016/j.ejvs.2016.10.023Diabetic foot ulcers and their treatment trajectories have
been widely investigated, but studies concerning delay in
revascularisation are scarce.5,6 The primary care centres play
a vital role in the early detection of inadequate arterial blood
supply in a diabetic foot,7,8 which is crucial for patient
prognosis.9,10 Once PAD is suspected, a vascular surgeon is
usually consulted and further investigations are conducted,
upon which the revascularisation plan is then based. Speciﬁc
target times for revascularisation are difﬁcult to establish
because of various referral patterns and very heterogeneous
ulcers. The guideline for the timing of revascularisation ac-
cording to previous studies can be encapsulated in thewords:
“the sooner, the better.”
According to the Finnish guidelines, whenever a tissue
lesion of suspected ischaemic origin is detected referral for
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Analysis of the Elective Treatment Process 207vascular evaluation is made, thus commencing the treat-
ment process at the vascular outpatient clinic in Helsinki
University Hospital (HUH). The aim has been to organise the
ﬁrst visit within 1 week of the referral for all these patients,
including all diabetic patients with an ulcer. After ankle
brachial index (ABI) and toe pressure (TP) measurements in
the vascular laboratory, vascular imaging, usually magnetic
resonance angiography (MRA), is scheduled, after which the
decision on treatment is made and revascularisation is
scheduled. If ischaemia is detected, the presence of an ulcer
is considered to be a sign of CLI and therefore revascular-
isation is scheduled within 2 weeks from the decision.
This retrospective study was launched in order to
determine the success of elective treatment of ischaemic
ulcers and to determine guidelines for the treatment pro-
cess. The main focus was on wound healing, the number of
emergency procedures while waiting for an elective pro-
cedure, and major amputations and deaths during follow-
up. Owing to the growing incidence of diabetes, there
was also focus on the treatment trajectories of diabetic foot
ulcers.ULCERS 235 ULCERS 159
Figure 1. The patients visiting senior consultant at Helsinki Uni-
versity Hospital vascular outpatient clinic in 2010e2011.MATERIALS AND METHODS
The study population for this retrospective study was
collected from the 2187 consecutive patients visiting the
senior vascular consultant’s outpatient clinic between
January 1 2010 and December 31 2011 (Fig. 1). The inclusion
criterion was a foot ulcer of suspected ischaemic origin
including all diabetic ulcers. The ABI was documented and
toe pressure (TP) measurements were taken at the
ﬁrst evaluation, but no threshold valueswere set for inclusion
in the study. In addition to the patients assigned for revas-
cularisation, the patients assigned for conservative treat-
ment were included, to gain a comprehensive perspective on
the entire elective treatment process.
The whole treatment process was analysed starting from
referral, with follow-up continuing until the end of 2013.
The time spent on each step of the treatment process from
referral to revascularisation was investigated. Cancellations
of the intended treatment, and the number as well as the
reasons for urgent diagnostics and treatments while waiting
for elective treatment were noted. The outcome of the
treatment process was analysed separately for endovas-
cular treatment (ET), open surgery (OS), and for patients
not receiving revascularisation. Wound healing was ana-
lysed during follow-up and healing was regarded as ach-
ieved when the wound had healed completely or was so
close to being healed that no further follow-up was
considered necessary. Limb salvage (LS) and amputation
free survival (AFS) were assessed by intention-to-treat (ITT)
analysis on the basis of the originally assigned treatment
and per treatment (PT) analysis according to the ﬁnal
revascularisation, that is the one that was considered to be
the ﬁrst successful one. For example, when OS was per-
formed after failed ET, the limb belonged to the OS group in
the PT analysis, but if a bypass graft undergoing surveillance
required ET due to stenosis or occlusion, the limb remainedin the OS group. The main focus in this study was the dia-
betic foot; therefore, their treatment process and outcome
during follow-up were analysed separately.
The demographic characteristics are expressed as per-
centages, and the delays in the treatment process as me-
dian days with interquartile ranges (IQR). LS and AFS were
assessed using the KaplaneMeier method. To assess the
independent risk factors for major amputation, univariate
analysis was performed followed by the Cox proportional
hazards model consisting of the factors reaching p < .2 in
the univariate analysis. Using univariate analysis, all the co-
morbidities, wound location, and delay to treatment were
tested. Multivariate analysis was performed for the overall
series and separately for diabetic and non-diabetic patients.
Statistical analysis was performed with the SPSS 19.0. sta-
tistical software (IBM SPSS Inc., Chicago, IL, USA).
RESULTS
Of the 969 ﬁrst evaluations for suspected PAD at the senior
consultant outpatient clinic during 2010e2011, 394 patients
with a total of 449 affected limbs had ulcers. The typical
patient in the study population lived at home, needed
walking assistance, had hypertension and diabetes, and was
on either antithrombotic or anticoagulant medication
(Table 1). The suspected ischaemic ulcer had normally exis-
ted for more than 1 month, was located in the forefoot, and
there had been no previous revascularisations (Table 2).
Treatment strategies
Revascularisation was scheduled for 233 patients with a
total of 248 affected limbs. The initial treatment strategy,
which was ET for 201 and OS for 47 limbs, changed for
Table 1. The characteristics of the 394 patients.
All (n ¼ 394) Diabetics
(n ¼ 242)
Non-diabetics
(n ¼ 152)
p
Age (years) 77.23 75.49 79.98 .001
Male (%) 52.0 58.3 42.1 .002
Living conditions (%)
Home 77.9 83.5 69.1 <.001
Assisted living 11.9 8.3 17.8 .005
Institution 10.4 8.3 13.2 .079
Mobility (%)
Unassisted 28.1 29.3 26.3 .023
Cane/walking aid 47.4 48.8 46.1 .515
Wheelchair 18.8 18.6 19.1 .905
Bedridden 5.5 3.3 8.6 .013
Comorbidities (%)
Hypertension 74.1 82.6 60.5 <.001
Coronary disease 42.1 47.5 32.9 .004
Lung disease 22.1 21.1 23.7 .055
Diabetes I and II 4.8 and 56.6 7.9 and 92.1 .0
Renal insufﬁciency 29.7 38.8 15.1 <.001
Rheumatoid disease 12.9 9.1 18.4 .007
Dementia 19.7 16.1 24.3 .044
Antithrombotic medication (%)
Aspirin 56.1 59.1 51.3 .208
Warfarin 24.6 27.3 20.4 .215
Clopidogrel 5.6 6.6 3.9 .586
Statin medication (%) 41.9 50.4 28.3 <.001
Smoking status (%)
Smoker 24.9 21.9 29.6 .085
Ex-smoker >5 years 20.8 24,4 14.5 .018
Non-smoker 20.6 23.6 16.4 .091
Not known 33.8 30.2 39.5 .057
208 K. Noronen et al.17.7% (n ¼ 44) limbs during the treatment process resulting
in 223 endovascular and 44 open procedures, as illustrated
in Fig. 2. After the ﬁrst endovascular treatment, 40.0%
(n ¼ 89) required additional revascularisations at the same
lesion site: 17.0% (n ¼ 38) underwent OS because of once
or twice failed ET, and 26.5% (n ¼ 59) underwent one to
nine (median 1) additional endovascular procedures during
follow-up because of failed or only partly successful ET.
After OS, 19.5% (n ¼ 16) received additional ET during
surveillance because of graft (n ¼ 15) and outﬂow stenosis
(n ¼ 1), and 15.9% (n ¼ 7) patients underwent re-
operation: one additional bypass after femoral endarterec-
tomy, three thrombectomies, and three bypasses because
of graft occlusion.
A decision on treatment was not reached for six patients:
three of them died within 3 weeks of the ﬁrst visit and
three did not attend either the scheduled imaging or the
follow-up for reasons unknown. For 195 patients no
revascularisation was planned, most commonly because of
anticipated spontaneous healing (n ¼ 95), after minor
amputation (n ¼ 21), or wound revision (n ¼ 4) (Table 3).
Delay
The median time from referral to revascularisation for the
whole study population was 45 (IQR 27e62) days. The delay
from referral to revascularisation was 44 (3e664) days for ET
alone and 51 (4e455) days for OS alone. For patientsundergoing OS after failed ET, the delay was 69 (19e780) days
(p < .04). The structure of the treatment process and the
delay at each step is presented in Fig. 3.Therewere 54 (20.3%)
urgent procedures, most of which (n¼ 29) were scheduled at
the ﬁrst outpatient clinic visit. The remaining 25 patients
arrived at the emergency room because of a worsened con-
dition while waiting for elective treatment. The reasons for
urgent procedureswere infection (n¼ 24), gangrene (n¼ 18),
and increased pain (n ¼ 12). Of the 24 patients with wound
infection, eight had elevated C-reactive protein above
100 mg/L and one had a septic infection with fever.
Limb salvage and amputation free survival
The 1 year LS for the different treatment strategies were
according to ITT analysis 81.6% (n ¼ 164) for ET, 89.4%
(n ¼ 42) for OS, and 85.6% (n ¼ 167) for conservative
treatment (p ¼ .201), and according to PT analysis 81.1%
(n ¼ 150) for ET, 92.7% (n ¼ 76) for OS, and 83.5%
(n ¼ 147) for conservative treatment (p ¼ .015). The 1 year
AFS according to ITT analysis was 57.2% (n ¼ 115) for ET,
55.3% (n ¼ 26) for OS, and 59.5% (n ¼ 116) for conservative
treatment (p ¼ .348), and according to PT analysis 57.3%
(n ¼ 106) for ET, 63.4% (n ¼ 52) for OS, and 59.7%
(n ¼ 105) for conservative treatment.
The overall LS across the whole follow-up period, in a
median of 25.9 (0.1e49.2) months, was, according to ITT
analysis, 77.1% (n ¼ 155) for ET, 89.4% (n ¼ 42) for OS, and
Table 2. Characteristics of the 449 affected limbs.
All
(n ¼ 449)
Diabetic
feet (n ¼ 273)
Non-diabetic
feet (n ¼ 176)
p
Amputation status (%)
Minor amputationa 10.5 13.2 6.3 .019
Major amputationb 3.8 5.1 1.7 .064
Previous revascularisation (%)
Angioplasty/stenting 8.9 10.6 6.3 .112
Bypass/Femoral endarterectomy 7.3 8.4 5.8 .277
Wound status (%)
Ulcer 82.9 79.9 87.5 .036
Gangrene 15.6 18.3 11.4 .047
Already healed 1.6 1.8 1.1 .561
Wound location (%)
Forefoot 55.9 59.3 50.0 .052
Heel 15.8 16.8 14.2 .453
Leg 20.0 16.2 26.1 .010
Forefoot þ heel 4.5 4.4 4.5 .940
Forefoot þ leg 2.7 1.8 4.0 .169
Heel þ leg 1.1 1.5 .6 .377
Forefoot, heel þ leg 0.2 0.0 .6 .212
Wound duration (%)
<1 month 25.2 27.8 21.0 .104
2 months 23.2 24.2 21.6 .526
3 months 10.7 11.0 10.2 .241
>3 months 26.5 24.5 29.5 .799
Not known 14.5 12.5 17.6 .129
Vascular laboratoryc
Ankle brachial index 0.85 0.95 0.65 .009
Toe pressure 36 41 31 <.001
a Ipsi-, contra-, or bilateral.
b Contralateral above the ankle amputation.
c Median values.
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Figure 2. Outcome of the different treatment strategies. Overall limb salvage (LS) and amputation free survival (AFS) after the ﬁnal
treatment. a Wound healing for patients undergoing secondary open surgery. b Wound healing for patients undergoing primary open
surgery.
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Table 3. The reasons for no revascularisation for 195 limbs, and their outcome.
All (n ¼ 195) DM (n ¼ 120) Non DM (n ¼ 75) p
Reasons (%)
Wound likely to heal.
spontaneously 48.7 59.2 32.0 <.001
after minor amputation/revision 12.8 11.7 14.7 .477
Major amputation needed 6.2 7.5 4.0 .322
Poor overall condition 26.2 13.3 46.7 <.001
Revascularisation not considered possible 5.1 6.7 2.7 .218
Patient refuses treatment 1.0 1.7 0 .261
Outcome (%)
Later revascularisation 15.9 17.5 13.3 .439
Major amputation 17.4 17.5 17.3 .976
Death 64.1 60.0 70.7 .131
Amputation free survival 29.7 34.2 22.7 .962
210 K. Noronen et al.73.3% (n ¼ 143) for conservative treatment. According to
PT analysis, LS was 76.8% for ET, 89.0% for OS (p ¼ .020),
and 81.3% (n ¼ 143) for conservative treatment. The overall
AFS according to ITT analysis was 38.8% (n ¼ 78) for ET and
38.3% (n ¼ 18) for OS, and according to PT analysis 37.3%
(n ¼ 69) for ET and 46.3% (n ¼ 38) for OS (Fig. 2). No
statistically signiﬁcant difference was found in overall AFS
between patients undergoing OS ﬁrst and patients under-
going OS after failed ET (45.5% vs. 47.4%, p ¼ NS), but LS
was better in the OS-ﬁrst group (95.5%) than in those
receiving OS after failed ET (81.6%) (p ¼ .045). Also, no
signiﬁcant difference was found for patients undergoing
emergency revascularisation (LS 79.2%, AFS 37.7%)
compared with those who underwent elective surgery (LS
80.0%, AFS 40.4%).
After univariate analysis the following factors were
included in the multivariate analysis: diabetes, coronary
disease, wound location, dementia, and delay from the
referral to the intervention (<2 weeks, 2 weeks). Inde-
pendent risk factors for major amputation in the overall
series were diabetes (OR 2.8, 95% CI 1.3e5.8), dementiaREFERRAL
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Figure 3. Delay on each step of the treatment process p(OR 2.5, 95% CI 1.22e5.22), and a wound located in the
heel (OR 1.3, 95% CI 1.1e1.5).Wound healing
Of the revascularised limbs, 81.6% (n ¼ 218) underwent
surveillance for wound healing whereas 27.3% (n ¼ 48) of
the conservatively treated limbs were followed in the
vascular department. Wound healing was achieved in a
median of 68 (0e1148) days. After revascularisation, wound
healing was achieved in 60.7% (n ¼ 162) of the limbs.
Wound healing was more likely after OS (76.8%) than after
ET (50.8%) (p< .001). The wound healing rate was the same
in patients undergoing OS as the ﬁrst line treatment as in
patients receiving OS after failed ET (NS).Diabetic foot
Diabetic patients formed the majority of this patient pop-
ulation (n ¼ 235, 67.3%), and of the 273 affected diabetic
feet 159 (58.2%) underwent revascularisation. Patients with
diabetes had more hypertension and coronary disease butREVASCULARISATION
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Analysis of the Elective Treatment Process 211were more often ambulatory and living at home than non-
diabetic patients (Table 1). The primary treatment was ET in
85.5% (n ¼ 136) of the diabetic feet and OS in 14.5%
(n ¼ 23). An additional 28 OS procedures after failed ET
took place resulting in 67.9% (n ¼ 108) diabetic feet un-
dergoing ET and 32.1% (n ¼ 51) OS.
Of the diabetic patients undergoing revascularisation,
84.3% (n ¼ 134) participated in follow-up, and wound
healing was achieved in a median of 78 (16e877) days for a
total of 61.6% (n ¼ 98) limbs, in 53.7% (n ¼ 58) feet after
ET, and in 78.4% (n¼ 40) after OS (p ¼ 0.003). There was no
signiﬁcant difference in wound healing compared with non-
diabetic patients (51.9%) after revascularisation (p ¼ .1).
The wound healing rate for those treated conservatively
was 19.8% (n ¼ 21).
In patients with diabetes, the median delay from referral
to revascularisation (45 [IQR 29e66] days) and the median
follow-up (25.9 months [22e146 days]) were similar to
those without diabetes. In multivariate analysis diabetes was
associated with inferior leg salvage (p ¼ .02), but no dif-
ference was seen in overall survival (p ¼ .1). When revas-
cularisation was performed within 2 weeks, there was no
difference in leg salvage between patients with and without
diabetes with 100% versus 92.9% at 30 days and 86.5%
versus 85.1% at 12 months respectively. When the delay
from referral to revascularisation exceeded 2 weeks, leg
salvage was signiﬁcantly poorer in patients with diabetes
(p < .001) (Fig. 4). When the multivariate analysis was
performed separately for diabetic and non-diabetic patients,
a delay of more than 2 weeks from the referral to revas-
cularisation appeared to be an independent predictor for
major amputation in diabetic patients (OR 3.1, 95% CI 1.4e
6.9), but not in non-diabetic patients.Figure 4. Limb salvage for diabetic patients and for patients with no dDISCUSSION
The treatment process of ischaemic ulcers can be described
as very complex even though the goal is very simple:
adequate blood ﬂow to the ischaemic wound area should
be restored. Ideally, the patient undergoes timely revascu-
larisation, the wound heals completely, and amputation is
avoided. In this study, delaying revascularisation past 2
weeks meant greater limb loss for diabetic than for non-
diabetic patients, a notable ﬁnding on a subject rarely
investigated.6 No signiﬁcant difference was found in overall
LS or AFS after revascularisation between patients with and
without diabetes. The overall wound healing rate and time
were also similar during follow-up and wound healing was
signiﬁcantly worse after ET for both groups (p < .001).
This study has some major limitations, the most impor-
tant one being its retrospective nature. Categorising the
ulcers and their progression rates retrospectively is
extremely difﬁcult, which is why all types of tissue loss have
been included in the study. They were divided into ulcers
and gangrene, but this division still does not describe the
healing potential sufﬁciently, as superﬁcial gangrene can
heal spontaneously, and, on the other hand, an extensive
ulcer might call for immediate amputation. Also, the data
on wound healing are inevitably crude regarding healing
times, since after the check at approximately 1 month, the
follow-up visits were assigned individually, and the data
were not available at all for many, especially for the patients
treated conservatively. The extent of the arterial disease
was disregarded in the analysis, which might also weaken
the reliability of the wound healing results, but does not
affect the treatment delays, for revascularisation is sched-
uled according to the clinical condition rather than the
arterial lesion.iabetes after a delay >2 weeks from referral to revascularisation.
212 K. Noronen et al.Including all the patients with tissue loss visiting the
outpatient clinic resulted in a very heterogeneous study
population with varying treatment patterns and times. This
diversity may inﬂuence the results, but it also provides a
comprehensive and a realistic perspective on the treatment
process.
For revascularisation to take place, ischaemia needs to be
detected ﬁrst. Diabetic ulcers are often detected late
because of neuropathy.11 When analyzing the treatment
process, the delay occurring before the referral either due to
the referring physician or for patient related reasons should
always be taken into account. In this study, 12 patients were
considered to need a major amputation at the ﬁrst visit to
the vascular outpatient clinic, and 29 patients needed urgent
revascularisation (Fig. 3). These patients reﬂect the delay
occurring prior to referral. On the other hand, at ﬁrst
assessment a wound may appear non-ischaemic and ABI
measurements may also be misleading,12,13 so the wound’s
potential to heal can be overestimated. In this series, 15.9%
(n ¼ 31) of the feet ﬁrst assigned to conservative treatment
eventually required revascularisation because of poor heal-
ing or a deterioration of the tissue lesion. To further evaluate
the healing potential, transcutaneous oxygen pressure
measurement has been shown to be effective especially
among diabetic patients,14 a method also routinely used in
Helsinki when wound healing seems uncertain.
The overall delay from referral to revascularisation of 45
(IQR 27e62) days can be considered prolonged even if the
individual steps in the process were not that long (Fig. 3).
The 25 (9.4%) urgent procedures reﬂect a delay in the
treatment process: while waiting for revascularisation, the
patient visits the emergency room due to a worsened ulcer
situation. This has also been noticed in everyday practice;
the number of patients with PAD visiting the emergency
room has risen in the recent years from 502 patients in
2010 to 699 in 2014.
When deciding on revascularisation, the ﬁrst decision is
often not the ﬁnal one. The possibility of changing the initial
plan is what makes vascular surgery versatile and inter-
esting, but it also makes the evaluation of the treatment
processes very challenging. A considerable amount of
crossover from ET to OS, 17.0% (n ¼ 38) occurred during
the study period, almost doubling the number (n ¼ 82) of
open procedures. The treatment philosophy is for the ma-
jority of the patients to have “endo ﬁrst,” even though OS
has been and is still today highly regarded in this clinic. In
addition, 15.9% (n ¼ 31) of the patients primarily treated
conservatively were later assigned to revascularisation. Re-
operations and additional treatments are also typical in
vascular surgery, in this study 38.6% (n¼ 103) underwent at
least one re-revascularisation, more commonly after ET
than after OS with 40.0% (n ¼ 89) versus 31.8% (n ¼ 14) of
the cases respectively (Fig. 2).
The “endo ﬁrst” philosophy has been shown to be
effective in previous studies from this institution15,16 and is
also established elsewhere17; it now gains some further
conﬁrmation since there was no signiﬁcant difference in the
wound healing or AFS between patients who underwent OSafter failed ET and those undergoing OS as the ﬁrst line
treatment. However, LS was inferior among these patients
undergoing OS as a second or third revascularisation as was
the LS in patients undergoing solely ET, results both possibly
affected by the longer delay from referral to successful
revascularisation. Nevertheless it would seem that instead
of “endo ﬁrst,” some patients would have beneﬁtted from
an “open only” approach.
Another probable underlying factor for the inferior LS
after ET is that when faced with the threat of major
amputation, the tendency is to optimistically perform ET
even when succeeding in revascularisation by any method
seems highly unlikely. The approach to treatment is also
well illustrated by the patient who underwent the most, a
total of 12, revascularisations, starting with two endovas-
cular treatments, then bypass surgery followed by seven
more ETs and two graft interpositions. The perseverance
was rewarded, for at the ﬁnal follow-up the graft was pat-
ent and the wound had healed 305 days later.
At the end of follow-up, the AFS was also inferior after ET
(37.3% vs. 46.3%), but with no statistical signiﬁcance and
overall, as low as was expected based on previous
publications.18,19
In all, 59.2% (n ¼ 266) of the limbs were followed for
wound healing, but only 26.0% of the patients treated
conservatively attended the surveillance. Needless to say,
their wound healing remains unclear and little emphasis can
be placed on the low percentage (17.6%) of healing ach-
ieved, especially when wound healing for those who
attended the surveillance was 64.6% (n ¼ 31) and 73.4%
died during the follow-up. On the other hand, 81.6% of the
revascularised limbs were surveyed, yielding fairly reliable
information on their wound healing, which was signiﬁcantly
better after OS than ET.CONCLUSIONS
According to this retrospective study, wound healing was
signiﬁcantly better after OS than after ET in the overall
study population and in patients with diabetes. Diabetic
patients achieved wound healing rates and times equal to
patients with no diabetes. However, diabetes was associ-
ated with inferior leg salvage if the delay before revascu-
larisation exceeded 2 weeks; therefore, timely
revascularisation is crucial, especially in diabetic patients.
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